4P-Pharma
Entity
Description
  • Value proposition

    Transforming science into drug success stories

    Established in 2014, 4P-Pharma is a clinical-stage biotech company dedicated to addressing serious diseases with significant unmet medical needs. Our goal is to bring first-in-class therapies to patients swiftly.​

    Our core is a specialized R&D engine that enhances risk management and accelerates the development process, effectively cutting down on time, costs, and uncertainty.​

    We focus on developing assets combining rapid time to market and solid intellectual property. Our strategy leverages cutting-edge clinical trial designs and expedited regulatory pathways to bring our therapies to those in need as quickly as possible.

    Translational research, Biotechnology, Pharmaceuticals, Inflammation, Abuse deterrent formulations, Research and Development, Drug Development, Preclinical development, Clinical development, Partnerships, Osteoarthritis, Covid-19, Age-related diseases, and Respiratory Infectious diseases

  • Original language

    Transforming science into drug success stories

    4P-Pharma est une société de biotechnologie lilloise au stade clinique fondée en 2014, qui se consacre à la régénération active de médicament dans l’objectif de développer des thérapies curatives pour des maladies graves non traitées.

    Notre démarche se différencie du développement pharmaceutique traditionnel par une approche de développement circulaire innovante, qui réduit le temps, les coûts et les risques, afin d’apporter des solutions thérapeutiques innovantes le plus rapidement possible aux patients. 4P-Pharma exploite des candidats médicaments dont le temps de développement est réduit notamment grâce à des opportunités règlementaires (« emergency use » ou autorisation conditionnelle de mise sur le marché) avec une forte propriété intellectuelle. 4P-Pharma se positionne ainsi dans des « blue-ocean markets ».

  • 4P Pharma, Translating Science to Medicine for Patients

    @4P Pharma is an R&D partner of academic and private institutions as well as life science investors. Our model is based on a co-risk co-share model.

    • https://4p-pharma.com/
Corporate interactions BETA
Corporate TypeTweets Articles
CNRS Innovation
CNRS Innovation
Research, Research Services
CNRS Innovation
Research, Research Services 		Other

7 Jun 2024


Clubster NSL
Clubster NSL
Public business cluster, French Cluster, Civic and Social Organizations
Clubster NSL
Public business cluster, French Cluster, Civic and Social Organizations 		Other

12 May 2024


Linkera
Linkera
Consulting, Information Services
Linkera
Consulting, Information Services 		Other

10 May 2024


LUTECH
LUTECH
LUTECH
Other

2 May 2024


Europe 1
Europe 1
Broadcast Media Production and Distribution
Europe 1
Broadcast Media Production and Distribution 		Other

3 Jul 2023


Le Figaro
Le Figaro
Media, Newspaper Publishing
Le Figaro
Media, Newspaper Publishing 		Other

16 May 2023


Business France
Business France
National and local authorities, Government Administration
Business France
National and local authorities, Government Administration 		Not capitalistic
Not partnership
Event

10 Jun 2021


BioValley France
BioValley France
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
BioValley France
Public business cluster, Biotechnology, French Cluster, Biotechnology Research 		Not capitalistic
Partnership
Event

6 Dec 2018


Servier Pharmaceuticals
Servier Pharmaceuticals
Pharmaceutical, Pharmaceutical Manufacturing
Servier Pharmaceuticals
Pharmaceutical, Pharmaceutical Manufacturing 		Not capitalistic
Partnership
Event

25 Nov 2014


Pfizer
Pfizer
Pharmaceutical, Pharmaceutical Manufacturing
Pfizer
Pharmaceutical, Pharmaceutical Manufacturing 		Not capitalistic
Partnership
Event

25 Nov 2014


Similar entities
Last news
Show all articles
Social network dynamics